# Evaluating an Artificial Intelligence software for opportunistic low bone mineral density and osteoporosis screening: a validation study

## TL;DR

This study validates an AI tool called Rho that can screen for low bone density and osteoporosis using radiographs, offering a potential alternative to limited DXA scans.

## Contribution

The study independently validates Rho AI software for opportunistic osteoporosis screening using real-world patient data.

## Key findings

- Rho achieved an AUC of 0.840 for predicting low BMD and 0.815 for osteoporosis.
- Performance was strong in both rural and urban populations, with AUCs of 0.873 and 0.865 for low BMD.
- Rho showed comparable effectiveness in men and women for low BMD prediction.

## Abstract

Despite the profound prevalence and fracture risk of osteoporosis, access to the gold standard DXA scans remains limited, especially in rural communities. Rho is an artificial intelligence software that can identify individuals at risk of low BMD and osteoporosis using radiographs. This study will independently validate Rho software by evaluating its performance against DXA in a retrospective cohort of patients. We conducted a retrospective study of 4878 patients (mean age 70 ± 10, 80% female), with DXA acquired within 1 yr of a radiograph. The area under the curve (AUC) was calculated to evaluate the performance of Rho in identifying patients at risk for low BMD (T-Score < −1) and osteoporosis (T-Score ≤ −2.5). Further subgroup analyses were performed based on radiograph location, sex, and rural vs urban populations. The overall AUC for predicting low BMD was 0.840 (95% CI: 0.831-0.848), with an optimal Rho score threshold of 6. For osteoporosis prediction, the AUC was 0.815 (95% CI: 0.806-0.824), with an optimal Rho score threshold of 7. Rural and urban populations have strong AUCs for low BMD (AUC = 0.873; 0.873) and osteoporosis (AUC = 0.865; 0.812). Likewise, Rho demonstrated strong, comparable (p > .25) performance in both men and women for prediction of low BMD. Although, optimal cutoffs differed between females and males for both low BMD and osteoporosis. Rho demonstrated high effectiveness in identifying patients at risk for low BMD and osteoporosis. The findings support Rho as an opportunistic screening tool and may fill a clinical gap in communities lacking access to DXA.